<DOC>
	<DOC>NCT01504581</DOC>
	<brief_summary>Study design: This is a randomized, double-blind, placebo- and active-controlled, single-dose study in 4 groups of 12 healthy male subjects each. In each group, 8 subjects will receive a dose of HM10660A, 2 subjects will receive a single dose of placebo and 2 subjects will receive a single dose of a currently marketed PEG-interferon.</brief_summary>
	<brief_title>Safety, Pharmacokinetic, Pharmacodynamic Study of LAPS-IFNa in Healthy Adult Subjects</brief_title>
	<detailed_description>Primary objective: to study the safety and tolerability of HM10660A, including immunogenicity, as compared to PEG-interferon alpha-2a Secondary objective: to study the pharmacokinetics and pharmacodynamics of HM10660A as compared to PEG-interferon alpha-2a</detailed_description>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Age: 18 45 Years, Inclusive BMI: 18.0 28.0 kg/m2 Are Nonsmokers or Smoker of Fewer Than 5 Cigarettes Per Day as Determined by History Mental Handicap Evidence of Clinically Relevant Pathology History of Type 1 Diabetes or Thyroid Disease</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>